Skip to main content
. 2017 Feb 9;12(2):e0171612. doi: 10.1371/journal.pone.0171612

Table 2. Assessment of the necrosis and degeneration.

Alternations/Groups Con. Puer. (50mg/kg) Cispt Cispt+10mg/kg Puer Cispt+30mg/kg Puer Cispt+50mg/kg Puer.
Necrosis and degeneration 0.00±0.00 0.00±0.00 3.48±0.26a 3.15±0.18b 2.31±0.15c 1.22±0.19c

a P<0.05 vs. Control group

b P>0.05 vs. Cisplatin group

c P<0.05 vs. Cisplatin group. Values are presented as the mean ± SD.

Note: Con.: control; Cispt: cisplatin; Puer.: Puerarin.